Nine NSCLC patients possess clinically described and significant mutations in prioritized genes involved in enriched KEGG pathways (TP53, PIK3CA, STATB5, BRCA1, KRAS, EGFR, and BAX). This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.